CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP [Hematologic Malignancy]
Conclusion
The CNS-IPI is a robust, highly reproducible tool that can be used to estimate the risk of CNS relapse/progression in patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Close to 90% of patients with DLBCL belong to the low- and intermediate-risk groups and have a CNS relapse risk < 5%; they may be spared any diagnostic and therapeutic intervention. In contrast, those in the high-risk group have a > 10% risk of CNS relapse and should be considered for CNS-directed investigations and prophylactic interventions.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Schmitz, Zeynalova, Nickelsen, Kansara, Villa, Sehn, Glass, Scott, Gascoyne, Connors, Ziepert, Pfreundschuh, Loeffler, Savage Tags: Prognostic Studies, Chemotherapy Hematologic Malignancy Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Hematology | Hodgkin's Disease | Lymphoma | Non-Hodgkin's Lymphoma | Prednisone | Rituxan | Study | Urology & Nephrology